相似文献
1
Dengue: a continuing global threat.
Nat Rev Microbiol. 2010 Dec;8(12 Suppl):S7-16. doi: 10.1038/nrmicro2460.
2
Dengue epidemiology: virus epidemiology, ecology, and emergence.
Adv Virus Res. 2003;61:235-89. doi: 10.1016/s0065-3527(03)61006-7.
3
Dengue fever in the Western Hemisphere.
Clin Lab Sci. 2003 Winter;16(1):34-8.
4
The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?
Comp Immunol Microbiol Infect Dis. 2004 Sep;27(5):319-30. doi: 10.1016/j.cimid.2004.03.013.
5
Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards.
PLoS Negl Trop Dis. 2010 Nov 16;4(11):e890. doi: 10.1371/journal.pntd.0000890.
6
Dengue virus.
Clin Lab Med. 2010 Mar;30(1):149-60. doi: 10.1016/j.cll.2009.10.007.
7
Increasing airline travel may facilitate co-circulation of multiple dengue virus serotypes in Asia.
PLoS Negl Trop Dis. 2017 Aug 3;11(8):e0005694. doi: 10.1371/journal.pntd.0005694. eCollection 2017 Aug.
8
Outwitting dengue threat and epidemics resurgence in Asia-Pacific countries: strengthening integrated dengue surveillance, monitoring and response systems.
Infect Dis Poverty. 2016 May 27;5(1):56. doi: 10.1186/s40249-016-0148-3.
9
History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: a review.
Parasit Vectors. 2018 Apr 24;11(1):264. doi: 10.1186/s13071-018-2830-8.
10
Epidemiological update on the dengue situation in the Western Pacific Region, 2012.
Western Pac Surveill Response J. 2015 Apr 20;6(2):82-9. doi: 10.5365/WPSAR.2014.5.4.002. eCollection 2015 Apr-Jun.
引用本文的文献
1
Forecasting Dengue: Evaluating the Role of Hydroclimate Information in Subseasonal to Seasonal Prediction.
Geohealth. 2025 Sep 1;9(9):e2024GH001325. doi: 10.1029/2024GH001325. eCollection 2025 Sep.
2
Recapitulating dengue virus infection with human pluripotent stem cell-derived liver organoids for antiviral screening.
Nat Commun. 2025 Aug 28;16(1):8069. doi: 10.1038/s41467-025-63323-3.
3
Mining of the Streptome Database for Hunting Putative Candidates to Allosterically Inhibit the Dengue Virus (Serotype 2) RdRp.
Pharmaceuticals (Basel). 2025 Jul 30;18(8):1135. doi: 10.3390/ph18081135.
4
and dengue: insights into transmission dynamics and viral lifecycle.
Epidemiol Infect. 2025 Aug 1;153:e88. doi: 10.1017/S0950268825100320.
5
Comparative analysis of phytocompounds and repurposed drugs against dengue virus serotypes employing an in silico study.
Sci Rep. 2025 Jul 30;15(1):27878. doi: 10.1038/s41598-025-06974-y.
6
Contrasted Ethnobotanical and Literature Knowledge of Anti-Mosquito Plants from Guadeloupe.
Biology (Basel). 2025 Jul 19;14(7):888. doi: 10.3390/biology14070888.
7
Seroprevalence of dengue virus infection among febrile patients visiting healthcare facilities in the selected districts of Afar region, Northeast Ethiopia.
BMC Infect Dis. 2025 Jul 28;25(1):948. doi: 10.1186/s12879-025-11406-3.
8
Sensitivity and Cross-Reactivity Analysis of Serotype-Specific Anti-NS1 Serological Assays for Dengue Virus Using Optical Modulation Biosensing.
Biosensors (Basel). 2025 Jul 14;15(7):453. doi: 10.3390/bios15070453.
9
Pharmacological Evaluation of active compounds in papaya associated with thrombocytopenia inhibition in dengue patients through in silico approaches.
Sci Rep. 2025 Jul 24;15(1):26922. doi: 10.1038/s41598-025-09835-w.
10
Molecular Epidemiology and evolutionary characteristics of dengue virus serotype-2 strains in Sri Lanka.
Res Sq. 2025 Jun 29:rs.3.rs-6726277. doi: 10.21203/rs.3.rs-6726277/v1.
本文引用的文献
1
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.
Cell Host Microbe. 2010 Sep 16;8(3):271-83. doi: 10.1016/j.chom.2010.08.007.
2
Cross-reacting antibodies enhance dengue virus infection in humans.
Science. 2010 May 7;328(5979):745-8. doi: 10.1126/science.1185181.
3
Recent expansion of dengue virus serotype 3 in West Africa.
Euro Surveill. 2010 Feb 18;15(7):19490.
4
A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.
J Infect Dis. 2010 Feb 1;201(3):370-7. doi: 10.1086/649916.
5
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.
Am J Trop Med Hyg. 2009 Nov;81(5):834-41. doi: 10.4269/ajtmh.2009.09-0131.
6
Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.
Am J Trop Med Hyg. 2009 Nov;81(5):825-33. doi: 10.4269/ajtmh.2009.08-0625.
7
Evaluation of commercially available anti-dengue virus immunoglobulin M tests.
Emerg Infect Dis. 2009 Mar;15(3):436-40. doi: 10.3201/eid1503.080923.
8
Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses.
Viral Immunol. 2008 Jun;21(2):123-32. doi: 10.1089/vim.2008.0007.
9
Levels of insecticide resistance and resistance mechanisms in Aedes aegypti from some Latin American countries.
J Am Mosq Control Assoc. 2007 Dec;23(4):420-9. doi: 10.2987/5588.1.
10
Dengue virus-mosquito interactions.
Annu Rev Entomol. 2008;53:273-91. doi: 10.1146/annurev.ento.53.103106.093326.
Zotero 插件